7th Jun 2019 12:11
LONDON (Alliance News) - Renalytix AI PLC on Friday announced positive results from at study of its FractalDx portfolio technology as a diagnostic tool in kidney transplant patients.
Shares in the kidney disease diagnostics company were up 7.6% at 240.00 pence shortly before mid day.
FractalDx technology was developed to detect acute transplant rejection in patients who have received a kidney transplant. In this study, which was published in the Journal of Clinical Investigation Insight, 235 kidney transplant recipients were tested using FractalDx.
A 23-gene set was identified that predicted early acute rejection and graft loss. The risk score created from this gene set was also significantly associated with acute cellular rejection six months after transplantation.
Results of the study indicate that FractaxDx could help personalise or even optimise immunosuppression therapy in kidney transplant patients, as patients who are less at risk could have their doses reduced to avoid toxic side effects.
Christian Larsen, a professor of surgery at Emory University School of Medicine and a member of Renalytix's kidney transplant advisory board, said: "This study offers the possibility to bring an individualised approach to the therapy selection for kidney transplant recipients, particularly in relation to selection of immunosuppression regimen.
"Current standard of care provides limited opportunity to identify patients most at risk of early acute rejection, and therefore the availability of a non-invasive blood test prior to transplant as presented in this publication, would represent a significant advance for the field."
Related Shares:
Renalytix Plc